重度肥胖者皮下脂肪组织衰老相关β-半乳糖苷酶与糖代谢异常及躯干脂肪相关
该前瞻性队列纳入227例重度肥胖患者,检测皮下和网膜脂肪组织的衰老相关β-半乳糖苷酶(SA-β-gal)活性。皮下脂肪SA-β-gal活性较网膜高七倍,且与胰岛素抵抗标志物、血清瘦素及躯干脂肪量正相关,糖尿病和血脂异常在高SA-β-gal者中更常见。
要点
- 皮下脂肪SA-β-gal活性显著高于网膜脂肪,且与BMI和年龄无关。
- 皮下脂肪SA-β-gal活性与胰岛素抵抗、瘦素及躯干脂肪量正相关。
- 高SA-β-gal者代谢并发症更常见,但减肥手术均可改善。
核心结论
- 重度肥胖者皮下脂肪组织存在衰老表型,且与糖代谢异常和体脂分布显著相关。
- 消除衰老细胞的senolytic治疗可能减轻重度肥胖者的代谢并发症。
研究设计与样本
- 前瞻性队列研究,纳入227例重度肥胖患者。
- 胃手术中获取配对皮下和网膜脂肪组织活检,用光度法量化SA-β-gal活性。
- 对脂肪组织活检及人原代前脂肪细胞进行基因和分泌谱分析,并测试senolytic药物效果。
主要发现
- 皮下脂肪SA-β-gal活性是网膜脂肪的七倍,且与BMI或实际年龄无关。
- IGFBP3、PAI1、CCL2和IL-6在皮下脂肪中与SA-β-gal相关上调(线性趋势P<0.05),在炎症巨噬细胞条件培养基培养的前脂肪细胞中亦上调。
- Senolytic治疗减少SA-β-gal染色并正常化上述改变。
- 皮下脂肪SA-β-gal活性与血清瘦素、胰岛素抵抗标志物及躯干脂肪量正相关。
- 2型糖尿病和血脂异常在高SA-β-gal患者中更普遍,但减肥手术后可改善,与初始衰老状态无关。
临床怎么用
- 皮下脂肪SA-β-gal活性可作为重度肥胖者糖代谢异常和躯干脂肪分布的潜在生物标志物。
- senolytic治疗可能为减轻重度肥胖代谢并发症提供新策略,但需进一步临床验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM/HYPOTHESIS: Altered adipose tissue secretory profile contributes to insulin resistance and type 2 diabetes in obesity. Preclinical studies have identified senescent cells as a cellular source of proinflammatory factors in adipose tissue of obese mice. In humans, potential links with obesity comorbidities are poorly defined. Here, we investigated adipose tissue senescent status and relationships with metabolic complications in human obesity. METHODS: The study includes a prospective cohort of 227 individuals with severe obesity. A photometric method was used to quantify senescence-associated β-galactosidase (SA-β-gal) activity in paired subcutaneous and omental adipose tissue biopsies obtained during gastric surgery. Gene and secretory profiling was performed in adipose tissue biopsies and in human primary pre-adipocytes in the presence or absence of senolytic drugs targeting senescent cells. Participants were phenotyped for anthropometric and bioclinical variables, metabolic complications and gastric surgery-induced improvement to address relationships with adipose tissue SA-β-gal. RESULTS: SA-β-gal activity was sevenfold higher in subcutaneous than in omental adipose tissue and not associated with BMI or chronological age. Several factors, including insulin-like growth factor binding protein 3 (IGFBP3), plasminogen activator inhibitor 1 (PAI1), C-C motif chemokine ligand 2 (CCL2) and IL-6, were upregulated in subcutaneous adipose tissue in relation with SA-β-gal (p for linear trend across tertiles <0.05) and in pre-adipocytes cultured with inflammatory macrophage conditioned media. Senolytic treatment reduced SA-β-gal staining and normalised these alterations. In the whole population, subcutaneous adipose tissue SA-β-gal activity was positively associated with serum leptin, markers of insulin resistance and increased trunk fat mass. Metabolic complications, including type 2 diabetes and dyslipidaemia, were more prevalent in patients with high levels of SA-β-gal, but improved with bariatric surgery whatever the initial adipose tissue senescent status. CONCLUSIONS/INTERPRETATION: This study highlights a phenotype of senescence in adipose tissue of severely obese individuals, which characterises prominently subcutaneous fat depots. Subcutaneous adipose tissue senescence is significantly linked to altered glucose metabolism and body fat distribution. Elimination of senescent cells through senolytic treatment could alleviate metabolic complications in severely obese people. Graphical abstract.
引用
- Rouault C, Marcelin G, Adriouch S, et al. Senescence-associated β-galactosidase in subcutaneous adipose tissue associates with altered glycaemic status and truncal fat in severe obesity. Diabetologia. 2020. PMID: 33125520. doi:10.1007/s00125-020-05307-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。